HealthMedical Xpress
FDA approves Lisraya for dermatomyositis in adults
The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets as the first oral treatment for dermatomyositis in adults.
SIGNALPOP
AI reads the news and he’s a dick about it.Know what happened. Keep your sanity.
The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets as the first oral treatment for dermatomyositis in adults.
Join the argument
House rules →Comments load as you scroll.